Patients with first or second recurrence of GBM will be treated with stereotactic injection
of the oncolytic virus DNX-2440.
After inclusion in the trial, stereotactic biopsy will be performed. In the same surgery, the
experimental agent will be injected also by stereotactic system, in a different part of the
lesion, in a region considered viable tumor, using a cannula especially designed for virus
Follow-up will include clinical visits and MRI No other treatment for the tumor will be used
until progression is documented. iRANO criteria and volumetric measurement of the tumor will
Any further treatment after progression will be at the criteria of the treating physician
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.